HPDL
4-hydroxyphenylpyruvate dioxygenase-like protein
Also known as: 4-HPPD-L, GLOXD1, HPDL_HUMAN, MGC15668
Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene
Protein identityUniProt · HPA
- UniProt accession
- Q96IR7
- Gene
- HPDL
- Ensembl
- ENSG00000186603
- Chromosome
- 1
- Canonical length
- 371 aa
- Protein class
- Disease related genes, Human disease related genes, Predicted intracellular proteins
- Subcellular location
- Nucleoplasm,Mitochondria
OverviewNCBI Gene
The protein encoded by this intronless gene localizes to mitochondria, where it may function as 4-hydroxyphenylpyruvate dioxygenase. Clinical studies have identified several bi-allelic variants in this gene that lower the level of the encoded protein and lead to a clinically variable form of pediatric-onset spastic movement disorder. [provided by RefSeq, Aug 2020]
Canonical amino-acid sequenceUniProt
371 residues, UniProt reviewed canonical sequence.
>Q96IR7|HPDL
1 MAAPALRLCH IAFHVPAGQP LARNLQRLFG FQPLASREVD GWRQLALRSG DAVFLVNEGA
61 GSGEPLYGLD PRHAVPSATN LCFDVADAGA ATRELAALGC SVPVPPVRVR DAQGAATYAV
121 VSSPAGILSL TLLERAGYRG PFLPGFRPVS SAPGPGWVSR VDHLTLACTP GSSPTLLRWF
181 HDCLGFCHLP LSPGEDPELG LEMTAGFGLG GLRLTALQAQ PGSIVPTLVL AESLPGATTR
241 QDQVEQFLAR HKGPGLQHVG LYTPNIVEAT EGVATAGGQF LAPPGAYYQQ PGKERQIRAA
301 GHEPHLLARQ GILLDGDKGK FLLQVFTKSL FTEDTFFLEL IQRQGATGFG QGNIRALWQS
361 VQEQSARSQE ALocalizationUniProt · AlphaFold · HPA
Whether an antibody against HPDL can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.
- Antibody reachability
- Intracellular
- Secreted
- No
- Transmembrane segments
- 0
- Mean surface accessibility (rSASA)
- 0.24
- Highest tissue expression
- 4 nTPM
Expression across tissuesHPA
Tissue
- cerebellum: 4 nTPM
- colon: 3.4 nTPM
- stomach: 3.1 nTPM
- basal ganglia: 2.6 nTPM
- rectum: 2.5 nTPM
- small intestine: 2.3 nTPM
Single-cell type
- cytotrophoblasts: 42 nCPM
- migrating cytotrophoblasts: 34 nCPM
- gastric progenitor cells: 23 nCPM
- enteric stem cells: 19 nCPM
- enteric transient amplifying cells: 15 nCPM
- megakaryocyte progenitors: 13 nCPM
Immune cell
- memory B-cell: 0.6 nTPM
- NK-cell: 0.4 nTPM
- MAIT T-cell: 0.3 nTPM
- memory CD8 T-cell: 0.2 nTPM
- myeloid DC: 0.2 nTPM
- naive CD4 T-cell: 0.2 nTPM
Brain region
- cerebellum: 7.8 nTPM
- medulla oblongata: 4 nTPM
- pons: 4 nTPM
- basal ganglia: 3.9 nTPM
- thalamus: 3.9 nTPM
- midbrain: 3.8 nTPM
DiseaseUniProt · ClinVar · IEDB · PubMed
Four sources answering four different questions about HPDL.
Disease | AllUniProt
Conditions HPDL is implicated in, by any mechanism.
- Neurodevelopmental disorder with progressive spasticity and brain white matter abnormalities (NEDSWMA) MIM:619026
- Spastic paraplegia 83, autosomal recessive (SPG83) MIM:619027
Disease | GeneticClinVar
48 pathogenic / likely-pathogenic of 125 ClinVar records.
Conditions with pathogenic or likely-pathogenic variants.
- Spastic paraplegia
- Neurodevelopmental disorder with progressive spasticity and brain white matter abnormalities
- Inborn genetic diseases
- Spastic paraplegia 83, autosomal recessive
- Spastic ataxia
Genetic constraint and essentialitygnomAD · DepMap
Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.
- gnomAD LOEUF (loss-of-function intolerance)
- 1.43
- gnomAD pLI
- 0
- gnomAD missense Z
- 0.93
- DepMap mean gene effect
- -0.07
- DepMap dependency class
- none
Cancer expressionTCGA
Across TCGA tumor cohorts, this protein is over-expressed in roughly 5% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).
OntologyGO
Biological processes
Molecular functions
- 4-hydroxyphenylpyruvate dioxygenase activity
- metal ion binding
- 4-hydroxymandelate synthase activity
Cellular components
Protein domainsUniProt · Pfam · InterPro
KeywordsUniProt
Antibody and autoantibody relevanceSeroatlas analysis
Seroatlas reads HPDL as an antibody target. Whether an autoantibody or antibody against HPDL could matter depends on whether native HPDL is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.
HPDL is annotated as predominantly intracellular. Intracellular proteins are common autoantibody markers, becoming visible to the immune system after cell injury or altered processing, but are usually markers of disease rather than direct drivers.
Annotation status
The present source text does not explicitly label HPDL as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.
Loading the interactive Seroatlas protein explorer...